Related Experiment Videos
Summary
Aluminum hydroxide gel in chronic renal failure patients can cause severe myopathy due to hypophosphatemia. Stopping antacid therapy and supplementing phosphate led to patient recovery.
Area of Science:
- Nephrology
- Neurology
- Biochemistry
Background:
- Chronic renal failure (CRF) patients often use aluminum hydroxide gel as a phosphate binder.
- Aluminum toxicity can manifest in various ways, including bone disease and neurological symptoms.
Observation:
- Three CRF patients developed severe proximal myopathy characterized by pain, stiffness, and weakness.
- Symptoms were initially misdiagnosed as uremic myopathy or rheumatoid arthritis exacerbation.
Findings:
- The myopathy was strongly associated with hypophosphatemia, linked to aluminum hydroxide gel use.
- Discontinuation of aluminum hydroxide gel and oral phosphate supplementation resulted in symptom resolution and recovery.
Implications:
- Highlights a specific iatrogenic cause of myopathy in CRF patients.
- Emphasizes the importance of monitoring phosphate levels and considering aluminum toxicity in CRF patients with unexplained myopathy.
- Suggests phosphate repletion as a therapeutic strategy for this condition.